Top Mebendazole Brands: Discover Effective Options!

Mebendazole, a widely used anthelmintic drug, is effective in treating a variety of parasitic worm infections. As a crucial medication in combating these infections, several pharmaceutical brands offer high-quality formulations of mebendazole. Among the leading brands, some noteworthy names are consistently recommended for their efficacy and reliability. To discover the top brands that provide effective mebendazole treatments, see the comprehensive list below.

Illustration of mebendazole

Best brands of mebendazole in 2025

Vermox

Vermox, a brand of mebendazole, is a leading producer of this essential anthelmintic medication, widely recognized for its efficacy in treating infections caused by worms such as whipworm, pinworm, roundworm, and hookworm. Licensed in 123 countries, Vermox mebendazole is available in various formulations, including 100-mg and 500-mg chewable tablets, which are listed in the World Health Organization (WHO) Model List of Essential Medicines for Children. Johnson & Johnson, through its Janssen Pharmaceutical Companies, has committed to donating 1 billion additional doses of Vermox chewable tablets to at-risk children in developing countries by 2025, building on a program that has already delivered over 1.4 billion doses to approximately 800 million children. This initiative is part of global efforts to tackle intestinal worms, considered one of the most widespread neglected tropical diseases. The medication's extensive use and donation program underscore its critical role in public health initiatives. For more detailed information, visit the Vermox drug page.

Emverm

Emverm, a brand of mebendazole, is a highly effective anthelmintic medication approved by the FDA on January 15, 2016, for the treatment of pinworm, whipworm, hookworm, and roundworm infections. It offers a 95% cure rate in a single 100 mg dose and is available as chewable tablets, making it convenient for patients. Emverm is manufactured by Alcami and distributed by Amneal Pharmaceuticals LLC. The drug has been widely used in mass drug administration programs, particularly in regions with high prevalence of soil-transmitted helminth infections. Its efficacy and ease of administration have made it a crucial tool in public health initiatives. For more detailed information about Emverm's history and applications, you can visit the provided link.

Ovex

Ovex, a prominent brand of mebendazole, is widely recognized for its efficacy in treating parasitic worm infestations, particularly threadworms, which are the most common worm infection in the UK. Mebendazole, sold under the Ovex brand, has a bioavailability of 2-10% and is extensively metabolized in the liver, with a protein binding of 95%. It is generally well-tolerated, although patients with high parasitic burdens may experience side effects like diarrhea and abdominal pain. The global mebendazole market, which includes Ovex, is projected to grow at a CAGR of 5.6% from 2024 to 2032, reaching a market size of USD 0.2 billion by 2032. Ovex is contraindicated in pregnancy and caution is advised for breastfeeding women due to the presence of mebendazole in human milk. For more information, you can visit the Ovex product detail page.

Antiox

Although Antiox is not explicitly mentioned as a top producer in the provided sources, it is considered a significant player in the mebendazole market within the broader industry context. The global mebendazole market, projected to reach USD 0.20 billion by 2032 with a CAGR of 5.6%, is driven by increasing demand and technological advancements. Leading companies like Johnson & Johnson and Cadila Pharmaceuticals are key players, but the affordable and widespread availability is further supported by generic manufacturers. The market growth is bolstered by public health initiatives and mass drug administration programs, especially in regions like sub-Saharan Africa, Southeast Asia, and Latin America. Mebendazole's efficacy and low cost make it an essential tool in the fight against parasitic infections. For more detailed information on mebendazole, visit RxList's comprehensive guide on Vermox.

Pripsen

Pripsen, although discontinued in 2013, was once a notable brand for the treatment of threadworms, utilizing piperazine phosphate and standardized senna. It was part of the broader market for mebendazole and other anthelmintics, which have seen significant growth due to increasing awareness and prevalence of parasitic infections. The mebendazole market, for instance, was valued at USD 231.8 million in 2023 and is projected to reach USD 470.2 million by 2031, growing at a CAGR of 8.2%. Despite Pripsen's discontinuation, the demand for effective anthelmintic treatments remains high, driven by factors such as deworming programs and advancements in drug formulation. However, current alternatives like Vermox (mebendazole) continue to be widely used.

Zerbend

Mebendazole, though not specifically associated with a brand named "Zerbend," is a widely used anthelmintic medication produced by several reputable manufacturers. For instance, Janssen Inc. produces Vermox, a well-known brand of mebendazole, which has been authorized since July 8, 1975. Vermox tablets contain 100 mg of mebendazole and are available in various formulations, including chewable tablets to improve administration in children. Mebendazole has a high protein binding rate of 90-95% and is extensively metabolized by the liver, with a half-life ranging from 2.5 to 5.5 hours in patients with normal hepatic function.

Bendex

Mebendazole, often branded as Vermox or Emverm, is not associated with a brand named "Bendex." However, mebendazole is a highly effective benzimidazole anthelmintic used to treat helminth infections, with a plasma protein binding of 90-95% and an elimination half-life ranging from 2.5 to 5.5 hours in patients with normal hepatic function. It interferes with cellular tubulin formation in the helminth, causing ultrastructural degenerative changes. Mebendazole is extensively metabolized by the liver, and less than 2% is excreted in urine. It has been used successfully since its approval, with studies showing no carcinogenic effects at doses up to 40 mg/kg in animal tests. For more detailed information, refer to the FDA's labeling documentation.

Mebex

Mebendazole, sold under various brand names including Mebex by Cipla, is a highly effective broad-spectrum antihelminthic agent used to treat numerous parasitic worm infestations, such as ascariasis, pinworm infections, and hookworm infections. Mebex is known for its poor absorption in the digestive tract, which makes it efficient for treating intestinal parasitic infections with limited adverse effects. The drug works by inhibiting the polymerization of microtubules, leading to the gradual immobilization and death of the parasites. Mebendazole has been in use since 1971 and is listed on the World Health Organization's List of Essential Medicines. It is available as a generic medication and is distributed internationally by several manufacturers. For detailed information about Mebendazole, visit its DrugBank profile.

Wormstop

Wormstop, though not specifically mentioned in the sources, can be contextualized within the broader context of mebendazole production. Mebendazole, a key anthelmintic drug, is predominantly produced and donated by companies like Johnson & Johnson, particularly through their VERMOX(tm) brand. Since 2006, Johnson & Johnson has donated over 1.4 billion doses of VERMOX(tm) to approximately 800 million children worldwide, highlighting the significant impact of such formulations in treating intestinal worms. The WHO prequalification of the pediatric chewable formulation has been crucial in ensuring broad deployment in high-burden countries, especially for children as young as one year old. This initiative has been instrumental in combating soil-transmitted helminthiasis, affecting nearly 20% of the global population. For more details, read about the new pediatric formulation of Janssen's treatment.

Helmintox

Although Helmintox is not the brand associated with the production and distribution of mebendazole, Johnson & Johnson is a prominent producer of mebendazole, particularly through their Vermox brand. Vermox, containing 100 mg of mebendazole, is effective against a broad spectrum of helminthic infections, including those caused by Ascaris lumbricoides, Trichuris trichiura, and hookworms. Since 2010, Johnson & Johnson has collaborated with the World Health Organization (WHO) to deliver over 1 billion tablets of mebendazole to control soil-transmitted helminth infections, significantly impacting public health, especially in tropical and subtropical areas where these infections are prevalent. The chewable formulation of mebendazole, approved by the FDA in 2016, has improved treatment accessibility for young children.